fluorouracil and Fibrosis, Radiation
fluorouracil has been researched along with Fibrosis, Radiation in 16 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pulmonary toxicity was prospectively evaluated within a randomized trial for breast cancer patients at high risk for relapse, who postoperatively received as adjuvant therapy either 9 cycles of tailored chemotherapy (20 patients) (cyclophosphamide, epirubicin, 5-fluorouracil [FEC]) or standard FEC x 3 followed by high-dose chemotherapy (cyclophosphamide, thiotepa, carboplatin [CTCb]) supported by peripheral blood stem cell transplantation (14 patients)." | 5.10 | Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. ( Bergh, J; Blomqvist, C; Hernberg, M; Keyriläinen, J; Maasilta, P; Virkkunen, P; Wiklund, T, 2002) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "Forty-four patients with esophageal squamous cell carcinoma (ESCC) were randomized into two groups." | 2.73 | [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. ( Chen, K; Gao, XS; Lin, Q; Qiao, XY; Wang, YD; Zhou, ZG, 2008) |
| "Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis." | 1.38 | Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012) |
| "Radiation pneumonitis was retrospectively graded using the Radiation Therapy Oncology Group (RTOG) scale by an observer blinded to the PET radiotoxicity score." | 1.37 | Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. ( Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP, 2011) |
| " Five cardiopulmonary toxic events of Grade 3 or greater were observed in 4 patients, Grade 5 heart failure and Grade 3 pericarditis in 1 patient, and Grade 3 myocardial infarction, Grade 3 radiation pneumonitis, and Grade 3 pleural effusion." | 1.35 | Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009) |
| "Thirty months after the right breast cancer treatment, Stage I left breast cancer was diagnosed." | 1.33 | A case of metachronous bilateral breast cancer with bilateral radiation pneumonitis after breast-conserving therapy. ( Araki, N; Hiraoka, M; Kawamura, S; Kodama, H; Mise, K; Mitsumori, M; Nagata, Y; Narabayashi, M; Oya, N; Sakamoto, T; Tachiiri, S; Yamauchi, C, 2006) |
Research
Studies (16)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Suh, YG | 1 |
| Lee, IJ | 1 |
| Koom, WS | 1 |
| Cha, J | 1 |
| Lee, JY | 1 |
| Kim, SK | 1 |
| Lee, CG | 1 |
| Su, J | 1 |
| Zhu, S | 1 |
| Liu, Z | 1 |
| Zhao, Y | 1 |
| Song, C | 1 |
| Lin, Q | 1 |
| Gao, XS | 1 |
| Qiao, XY | 1 |
| Chen, K | 1 |
| Wang, YD | 1 |
| Zhou, ZG | 1 |
| Morota, M | 1 |
| Gomi, K | 1 |
| Kozuka, T | 1 |
| Chin, K | 1 |
| Matsuura, M | 1 |
| Oguchi, M | 1 |
| Ito, H | 1 |
| Yamashita, T | 1 |
| Mac Manus, MP | 1 |
| Ding, Z | 1 |
| Hogg, A | 1 |
| Herschtal, A | 1 |
| Binns, D | 1 |
| Ball, DL | 1 |
| Hicks, RJ | 1 |
| Bourgier, C | 1 |
| Pessoa, EL | 1 |
| Dunant, A | 1 |
| Heymann, S | 1 |
| Spielmann, M | 1 |
| Uzan, C | 1 |
| Mathieu, MC | 1 |
| Arriagada, R | 1 |
| Marsiglia, H | 1 |
| Erven, K | 1 |
| Weltens, C | 1 |
| Nackaerts, K | 1 |
| Fieuws, S | 1 |
| Decramer, M | 1 |
| Lievens, Y | 1 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 1 |
| Lind, PA | 2 |
| Marks, LB | 2 |
| Jamieson, TA | 1 |
| Carter, DL | 1 |
| Vredenburgh, JJ | 1 |
| Folz, RJ | 1 |
| Prosnitz, LR | 2 |
| Yamashita, H | 1 |
| Nakagawa, K | 1 |
| Tago, M | 1 |
| Igaki, H | 1 |
| Nakamura, N | 1 |
| Shiraishi, K | 1 |
| Sasano, N | 1 |
| Ohtomo, K | 1 |
| Narabayashi, M | 1 |
| Mitsumori, M | 1 |
| Araki, N | 1 |
| Yamauchi, C | 1 |
| Kawamura, S | 1 |
| Sakamoto, T | 1 |
| Tachiiri, S | 1 |
| Oya, N | 1 |
| Nagata, Y | 1 |
| Hiraoka, M | 1 |
| Mise, K | 1 |
| Kodama, H | 1 |
| Wang, S | 1 |
| Liao, Z | 1 |
| Wei, X | 1 |
| Liu, HH | 1 |
| Tucker, SL | 1 |
| Hu, C | 1 |
| Ajani, JA | 1 |
| Phan, A | 1 |
| Swisher, SG | 1 |
| Mohan, R | 1 |
| Cox, JD | 1 |
| Komaki, R | 1 |
| Mah, K | 1 |
| Keane, TJ | 1 |
| Van Dyk, J | 1 |
| Braban, LE | 1 |
| Poon, PY | 1 |
| Hao, Y | 1 |
| Hardenbergh, PH | 1 |
| Clough, R | 1 |
| Fan, M | 1 |
| Hollis, D | 1 |
| Hernando, ML | 1 |
| Lucas, D | 1 |
| Piepgrass, A | 1 |
| Hernberg, M | 1 |
| Virkkunen, P | 1 |
| Maasilta, P | 1 |
| Keyriläinen, J | 1 |
| Blomqvist, C | 1 |
| Bergh, J | 1 |
| Wiklund, T | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Kouroussis, C | 1 |
| Kakolyris, S | 1 |
| Sivridis, E | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study[NCT04212598] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study[NCT00594477] | Phase 1 | 100 participants (Actual) | Interventional | 2008-01-04 | Completed | ||
| Proton Therapy for Peripheral Lymph Nodes in Breast Cancer[NCT01365845] | 18 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Volume of Heart Receiving ≥ 5 Gray (Gy)/Cobalt Gray Equivalent (CGE)
A reduction of 50% in heart volume exposed to radiation doses ≥ 5 Gy/CGE was considered preferred outcome in this study plan. (NCT01365845)
Timeframe: 2 weeks prior to starting radiation therapy.
| Intervention | % of heart receiving >= 5 Gray (Gy) (Median) |
|---|---|
| Conventional Photon Plan | 34.7 |
| 3D-Proton/Conventional Plan or 3D-proton Only | 2.7 |
Reviews
1 review available for fluorouracil and Fibrosis, Radiation
| Article | Year |
|---|---|
Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Com | 2002 |
Trials
4 trials available for fluorouracil and Fibrosis, Radiation
| Article | Year |
|---|---|
[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Combined Modality | 1994 |
Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Admi | 2002 |
Other Studies
11 other studies available for fluorouracil and Fibrosis, Radiation
| Article | Year |
|---|---|
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2017 |
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2009 |
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma | 2012 |
Changes in pulmonary function up to 10 years after locoregional breast irradiation.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2012 |
The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
A case of metachronous bilateral breast cancer with bilateral radiation pneumonitis after breast-conserving therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; | 2006 |
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Dose-Response Relationship | 2008 |
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F | 2002 |
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F | 2002 |
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F | 2002 |
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F | 2002 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |